FFFloyd J. Frost

Floyd J. Frost

*This is an algorithmically generated author record based on publicly available information.

Floyd J. Frost has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 July 2010
      • Vol. 16  (7) , 505-12

    Can outpatient pharmacy data identify persons with undiagnosed COPD?

    by Douglas W Mapel, Hans Petersen, Melissa H Roberts, Judith S Hurley, Floyd J Frost, Jeno P Marton

    To develop and validate a method for identifying persons with undiagnosed chronic obstructive pulmonary disease (COPD) using outpatient pharmacy data. Case-control analysis of managed care administrative data with clinical validation by spirometry and standardized questionnaires. Patients with a new diagnosis of COPD were matched to 3 control subjects by age and sex. Outpatient pharmacy utilization for the 2 years prior to the initial diagnosis was captured. Drugs associated with an eventual diagnosis of COPD were identified using conditional logistic regression, and then entered into a predictive algorithm using discriminant function analysis. The algorithm was tested in a second population from the same health plan and externally validated using 2 large multicenter databases. This system was clinically validated by testing 100 individuals identified by the algorithm with spirometry plus health status and respiratory symptoms questionnaires. COPD patients used significantly more antibiotics, cardiac medications, and respiratory drugs than their matched controls. The final algorithm identified COPD patients with a sensitivity of 60% and specificity of 70%, without the benefit of knowing any patient's smoking history. Of the first 100 persons identified by the algorithm as being at risk and recruited for testing, 25 were proven to have previously undiagnosed COPD. Pharmacy utilization increases in the years prior to initial COPD diagnosis. Algorithms based on pharmacy utilization can efficiently identify persons at risk for undiagnosed COPD.


  • Statins Have No Role in Pulmonary Disease Mortality: Response

    by Floyd Frost

  • Statins and Influenza/COPD Mortality: Response

    by Floyd Frost

  • Open Access

    Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study

    by Soe Soe Thwin, Kerri M Clough-Gorr, Maribet C McCarty, Timothy L Lash, Sharon H Alford, Diana Sm Buist, Shelley M Enger, Terry S Field, Floyd Frost, Feifei Wei, et al.

    The choice between paper data collection methods and electronic data collection (EDC) methods has become a key question for clinical researchers. There remains a need to examine potential benefits, efficiencies, and innovations associated with an EDC system in a multi-center medical record review study.


  • Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins

    by Floyd J. Frost, Hans Petersen, Kristine Tollestrup, Betty Skipper


  • Analysis of serological responses to cryptosporidium antigen among NHANES III participants

    by Floyd J. Frost, Timothy B. Muller, Rebecca L. Calderon, Gunther F. Craun


  • Open Access

    Identifying US populations for the study of health effects related to drinking water arsenic

    by Floyd J Frost, Timothy Muller, Hans V Petersen, Bruce Thomson, Kristine Tollestrup

    The US Environmental Protection Agency recently set a new maximum contaminant level (MCL) for arsenic in drinking water of 10 μg/l. In this paper, we review the completeness and accuracy of drinking water arsenic occurrence data in the United States and identify populations exposed to elevated arsenic concentrations that would be suitable for epidemiological studies of arsenic health effects. Using existing data from the Environmental Protection Agency Arsenic Occurrence and Exposure Database and additional data from state health and environment departments and water utilities, we identified 33 counties in 11 states with an estimated mean drinking water arsenic concentration of 10 μg/l or greater. A total of 11 of these ‘confirmed’ counties had an estimated mean arsenic concentration of 20 μg/l or more and two had an estimated mean arsenic concentration 50 μg/l or more. Based on census data, between 1950 and 1999 there were approximately 51.1 million person-years of exposure to drinking water arsenic at levels of 10 μg/l or more, 8.2 million at levels of 20 μg/l or more arsenic and 0.9 million at levels of 50 μg/l or more. Mortality and incidence of diseases known to be associated with arsenic exposure can and should be examined in these counties as part of a comprehensive assessment of arsenic health effects in US populations.


  • Quality Assurance Considerations in Cryptosporidium Antibody Tests

    by Floyd Frost, Tim Muller, Twila Kunde, Gunther Craun

    Priest et al. (12) reported a comparison of serological tech- niques to detect responses to two Cryptosporidium antigens. They compared a low-cost minigel format blot assay that we developed with a Centers for Disease Control and Preven- tion (CDC)-developed enzyme-linked immunosorbent assay (ELISA) and a large-format gel. The minigel analysis was performed in a British Columbia laboratory. The minigel and large-format gel detected similar positive and negative re- sponses to the 15- and 17-kDa antigens; however, the CDC ELISA had 23% false-positive responses and 12% false-nega- tive responses to the 15- to 17-kDa antigen. For the 27-kDa antigen, the large-format gel detected more positive responses than did either the minigel or ELISA. In 1996, we trained the British Columbia staff in Albuquer- que to conduct our minigel assay and provided copies of our quality assurance (QA) procedures. These procedures require computer imaging of the blots and rejecting blots with a weak positive control (PC) or when the coefficient of variation (CV) for duplicate PCs is greater than 35% (3). When contacted, Dr. Priest stated that the blots used in their publication were not computer imaged and that QA procedures were informally conducted by manual inspection. Although we requested com- puter images of these blots for additional QA evaluation, they were not made available to us. To reduce costs, the minigel uses only a small fraction of the antigen needed for either the ELISA or large-format blot. As a result, considerable care must be taken to minimize sources of variance and to insure that the antigen is uniformly applied across the blot. In addition, since we are interested in both detecting a response and measuring the intensity of that re- sponse, it is critical that blot performance be continuously monitored. Since responses tend to fade over time, the imaging must be done shortly after the blots are completed to avoid underestimating the CV. Because the cost of the minigel assay is dramatically lower than the cost of the large-format gel assay and, we believe, lower than the cost of the ELISA, we compared performance of the minigel to that of the large-format gel. The large-format gel assay was used as the standard of comparison by Priest et al. We compared detection of a response to each antigen for 42 samples from two prior studies (3, 4). Concordance in detec- tion was 79% for the 15- to 17-kDa antigen and 86% for the 27-kDa antigen. The minigel detected six responses to the 15- to 17-kDa antigen and three to the 27-kDa antigen that the large gel missed. The large gel detected three responses to the 15- to 17-kDa antigen and three to the 27-kDa antigen that the minigel missed. These data indicate that the minigel assay, with appropriate quality control procedures, can generate findings comparable to those for the large-format gel assay at a small fraction of the cost.